AngioDynamics, Inc. (ANGO) Insider Trading Activity
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
ANGO Insider Trading Activity
ANGO Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $135,847 | 4 | 80 |
Sells | $49,979 | 1 | 20 |
Related Transactions
| Clemmer James C | President and CEO | 1 | $120,600 | 0 | $0 | $120,600 |
| Trowbridge Stephen A | EVP and CFO | 1 | $9,962 | 0 | $0 | $9,962 |
| Nighan Warren JR | SVP Quality and Regulatory | 2 | $5,285 | 1 | $49,979 | $-44,693 |
About AngioDynamics, Inc.
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
Insider Activity of AngioDynamics, Inc.
Over the last 12 months, insiders at AngioDynamics, Inc. have bought $135,847 and sold $49,979 worth of AngioDynamics, Inc. stock.
On average, over the past 5 years, insiders at AngioDynamics, Inc. have bought $309,940 and sold $590,403 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Clemmer James C (President and CEO) — $120,600. Trowbridge Stephen A (EVP and CFO) — $9,962. Nighan Warren JR (SVP Quality and Regulatory) — $5,285.
The last purchase of 100 shares for transaction amount of $608 was made by Nighan Warren JR (SVP Quality and Regulatory) on 2024‑10‑10.
List of Insider Buy and Sell Transactions, AngioDynamics, Inc.
| 2025-01-16 | Sale | Nighan Warren JR | SVP Quality and Regulatory | 4,060 0.0096% | $12.31 | $49,979 | -25.29% | |
| 2024-10-10 | Nighan Warren JR | SVP Quality and Regulatory | 100 0.0002% | $6.08 | $608 | +50.98% | ||
| 2024-10-08 | Trowbridge Stephen A | EVP and CFO | 1,700 0.0033% | $5.86 | $9,962 | +57.48% | ||
| 2024-10-07 | Clemmer James C | President and CEO | 20,000 0.0399% | $6.03 | $120,600 | +51.72% | ||
| 2024-10-07 | Nighan Warren JR | SVP Quality and Regulatory | 768 0.0015% | $6.09 | $4,677 | +51.72% | ||
| 2024-04-08 | Clemmer James C | President and CEO | 10,000 0.0254% | $6.70 | $67,000 | +11.95% | ||
| 2023-01-31 | Sale | Helsel Dave | SVP Global Operations and R&D | 4,633 0.0117% | $12.95 | $59,997 | -34.26% | |
| 2022-10-12 | Trowbridge Stephen A | EVP and CFO | 1,083 0.0027% | $13.82 | $14,967 | -23.56% | ||
| 2022-10-10 | Clemmer James C | President and CEO | 10,000 0.0264% | $15.00 | $150,000 | -24.97% | ||
| 2022-07-29 | Sale | Helsel Dave | SVP Global Operations and R&D | 5,000 0.0126% | $22.44 | $112,200 | -43.39% | |
| 2022-04-28 | Sale | Helsel Dave | SVP Global Operations and R&D | 3,513 0.009% | $22.44 | $78,832 | -37.25% | |
| 2022-04-12 | Sale | JOHNSON WESLEY | director | 1,299 0.0034% | $23.26 | $30,215 | -34.97% | |
| 2022-04-11 | Sale | JOHNSON WESLEY | 7,500 0.0197% | $23.05 | $172,838 | -31.92% | ||
| 2022-01-12 | Trowbridge Stephen A | EVP and CFO | 2,000 0.0052% | $22.64 | $45,280 | -6.16% | ||
| 2022-01-11 | Clemmer James C | President and CEO | 20,000 0.0498% | $22.84 | $456,800 | -11.60% | ||
| 2021-10-20 | Sale | Helsel Dave | SVP Global Operations and R&D | 6,988 0.0176% | $27.97 | $195,454 | -21.70% | |
| 2021-10-15 | Sale | Centea Scott | Sr. VP/GM, Global VIT | 24,000 0.0627% | $27.92 | $670,080 | -18.23% | |
| 2021-10-05 | Sale | Campbell Chad Thomas | SVP/GM, Vascular Access | 21,496 0.0543% | $27.15 | $583,616 | -17.96% | |
| 2021-04-14 | Sale | Helsel Dave | SVP Global Operations and R&D | 7,000 0.0182% | $23.93 | $167,510 | +6.62% | |
| 2021-01-20 | Sale | JOHNSON WESLEY | director | 13,000 0.0335% | $18.53 | $240,890 | +35.77% |
Insider Historical Profitability
| Clemmer James C | President and CEO | 681582 1.6785% | $6.33M | 8 | 0 | +14.4% |
| Trowbridge Stephen A | EVP and CFO | 172711 0.4253% | $1.6M | 4 | 2 | +31.28% |
| Nighan Warren JR | SVP Quality and Regulatory | 41817 0.103% | $388,479.93 | 2 | 1 | |
| STERN HOWARD S | director, 10 percent owner | 1647687 4.0576% | $15.31M | 0 | 35 | |
| Burgstahler David F | 381406 0.9393% | $3.54M | 0 | 3 | ||
| Avista Capital Partners GP, LLC | 10 percent owner | 381406 0.9393% | $3.54M | 0 | 3 | |
| MEYERS DAVID P | director | 336980 0.8299% | $3.13M | 0 | 33 | |
| HOBBS EAMONN P | President & CEO | 100401 0.2473% | $932,725.29 | 3 | 27 | +11.44% |
| BUCCI VINCENT | director | 86696 0.2135% | $805,405.84 | 9 | 0 | <0.0001% |
| JOHNSON WESLEY | director | 79704 0.1963% | $740,450.16 | 2 | 3 | <0.0001% |
| Gould Kevin J | director | 55124 0.1357% | $512,101.96 | 3 | 1 | +8.54% |
| DONNELLY HOWARD W | director | 47600 0.1172% | $442,204.00 | 3 | 1 | +17.81% |
| Centea Scott | Sr. VP/GM, Global VIT | 46244 0.1139% | $429,606.76 | 0 | 1 | |
| DEVIVO JOSEPH | President and CEO | 38000 0.0936% | $353,020.00 | 4 | 0 | <0.0001% |
| ECHENBERG PAUL S | Director Emeritus | 31976 0.0787% | $297,057.04 | 0 | 1 | |
| Campbell Chad Thomas | SVP/GM, Vascular Access | 31741 0.0782% | $294,873.89 | 0 | 1 | |
| Kapusta Matthew C | SVP, Business Development | 27005 0.0665% | $250,876.45 | 2 | 0 | +8.01% |
| GOLD JEFFREY | director | 25233 0.0621% | $234,414.57 | 1 | 1 | +6.67% |
| Meteny Dennis S | director | 21950 0.0541% | $203,915.50 | 2 | 0 | +16.07% |
| Greiner Charles R | VP - Global Franchise | 20910 0.0515% | $194,253.90 | 0 | 5 | |
| Greiner Michael | EVP and CFO | 20731 0.0511% | $192,590.99 | 0 | 1 | |
| Richard Stark | SVP, GM - Oncology | 20754 0.0511% | $192,804.66 | 0 | 4 | |
| Helsel Dave | SVP Global Operations and R&D | 19189 0.0473% | $178,265.81 | 0 | 5 | |
| Keltjens Jan | President & CEO | 15000 0.0369% | $139,350.00 | 4 | 0 | +18.72% |
| LaPorte Steve | director | 8013 0.0197% | $74,440.77 | 8 | 0 | +1.5% |
| Shea Paul J | VP - Sales | 2562 0.0063% | $23,800.98 | 0 | 13 | |
| Orsatti Charles Thomas | director | 2000 0.0049% | $18,580.00 | 1 | 0 | +20% |
| FLAHERTY ROBERT E | director | 1200 0.003% | $11,148.00 | 1 | 0 | +19.04% |
| ROSSELL ROBERT M | VP - Marketing | 1000 0.0025% | $9,290.00 | 1 | 7 | +116.9% |
| RECINELLA DANIEL | VP - Product Development | 892 0.0022% | $8,286.68 | 0 | 3 | |
| Stern Linda B | 10 percent owner | 891 0.0022% | $8,277.39 | 0 | 26 | |
| APPLING WILLIAM M | Vice-President - Research | 654 0.0016% | $6,075.66 | 0 | 17 | |
| Casciaro Gregory D | director | 500 0.0012% | $4,645.00 | 1 | 0 | +19.04% |
| REED JAN STERN | director | 316 0.0008% | $2,935.64 | 1 | 0 | +2.38% |
| GERARDI JOSEPH G | Vice President | 242 0.0006% | $2,248.18 | 0 | 25 | |
| KUNST BRIAN | VP - Regulatory Affairs | 0 0% | $0 | 0 | 6 | |
| MAPES HAROLD | VP - Operations | 0 0% | $0 | 0 | 12 |
ANGO Institutional Investors: Active Positions
| Increased Positions | 76 | +48.72% | 8M | +26.18% |
| Decreased Positions | 69 | -44.23% | 4M | -13.73% |
| New Positions | 29 | New | 4M | New |
| Sold Out Positions | 19 | Sold Out | 2M | Sold Out |
| Total Postitions | 163 | +4.49% | 36M | +12.45% |
ANGO Ownership Change vs Market
Institutional Investor Ownership
| Blackrock, Inc. | $33,407.00 | 8.77% | 3.6M | -345,588 | -8.77% | 2025-03-31 |
| Systematic Financial Management Lp | $23,421.00 | 6.15% | 2.52M | +110,719 | +4.59% | 2024-12-31 |
| Vanguard Group Inc | $21,298.00 | 5.59% | 2.29M | +2,764 | +0.12% | 2024-12-31 |
| Millennium Management Llc | $20,090.00 | 5.28% | 2.16M | -72,884 | -3.26% | 2024-12-31 |
| Dimensional Fund Advisors Lp | $13,830.00 | 3.63% | 1.49M | +135,007 | +9.97% | 2024-12-31 |
| Segall Bryant & Hamill, Llc | $12,861.00 | 3.38% | 1.38M | -30,717 | -2.17% | 2025-03-31 |
| Nuveen Asset Management, Llc | $12,043.00 | 3.16% | 1.3M | +353,070 | +37.43% | 2024-12-31 |
| Royce & Associates Lp | $10,399.00 | 2.73% | 1.12M | +133,312 | +13.52% | 2024-12-31 |
| Geode Capital Management, Llc | $9,051.00 | 2.38% | 974,302 | +13,535 | +1.41% | 2024-12-31 |
| Ubs Group Ag | $8,756.00 | 2.3% | 942,565 | +916,541 | +3,521.91% | 2024-12-31 |